Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.
about
Structure of the human serotonin 5-HT4 receptor gene and cloning of a novel 5-HT4 splice variantReview article: tegaserod.Tegaserod for constipation-predominant irritable bowel syndrome.Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disordersTegaserod: a new 5-HT(4) agonist in the treatment of irritable bowel syndrome.The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.Effects of tegaserod and erythromycin in upper gut dysmotility: a comparative study.Tegaserod pharmacokinetics are similar in patients with severe renal insufficiency and in healthy subjects.The pharmacokinetics of the novel promotile drug, tegaserod, are similar in healthy subjects-male and female, elderly and young.The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjects.Tegaserod, a 5-HT4 receptor partial agonist, accelerates gastric emptying and gastrointestinal transit in healthy male subjects.Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects.Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4 agonist tegaserod.Preconcentration and Differential Pulse Voltammetry of Tegaserod at a Glassy Carbon Electrode
P2860
Q28369138-4486D6ED-9A91-48D3-A6EA-D18607B65A0FQ32026539-000289D7-F2D6-4C9D-951D-73A97E1A2CA9Q33436477-3877B848-F37E-468B-96DF-1474E55F3DF4Q34166903-2C35E0D6-0FAF-49F9-AEB4-9852E164D3D3Q34768534-60B62241-3968-4737-AE72-BEEF759DCE22Q36407290-B97B8D0C-4626-4E45-81A7-7CCD9FBF5F21Q37442961-5554B267-7C28-4A3A-912F-C1AEA7C46148Q42598244-7BB8BF1D-7905-48A4-A056-D52241F26190Q43650347-16F530F2-ABDA-4273-B078-A88A7997287AQ43754379-4F3F3719-88E4-4699-8FCB-9EA56B708A29Q43782284-FB3F34BC-4436-4BD9-832C-DB4BE28683EDQ44162437-99D3655C-7770-44BE-96B4-05A938A03640Q44914306-75590ADB-F83F-4563-926E-B6EF9723C327Q58291995-F92C0A18-E2D4-4302-BBD2-0B49B0611DBF
P2860
Integrated modelling of the clinical pharmacokinetics of SDZ HTF 919, a novel selective 5-HT4 receptor agonist, following oral and intravenous administration.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Integrated modelling of the cl ...... nd intravenous administration.
@ast
Integrated modelling of the cl ...... nd intravenous administration.
@en
type
label
Integrated modelling of the cl ...... nd intravenous administration.
@ast
Integrated modelling of the cl ...... nd intravenous administration.
@en
prefLabel
Integrated modelling of the cl ...... nd intravenous administration.
@ast
Integrated modelling of the cl ...... nd intravenous administration.
@en
P2093
P2860
P1476
Integrated modelling of the cl ...... nd intravenous administration.
@en
P2093
E Legangneux
M O Lemarechal
S Appel-Dingemanse
P2860
P304
P356
10.1046/J.1365-2125.1999.00936.X
P407
P577
1999-05-01T00:00:00Z